Medical Watch Disease & Treatment News

Scientific progress in gene and cell therapies has outpaced European healthcare systems' ability to deliver them.

• Only 18% of eligible patients...

Proteomics is shifting diagnostics earlier through targeted protein panels validated in large biobanks, such as an 18-biomarker blood test tracking...

The FDA approved Rasonque (daraxonrasib), the first targeted RAS inhibitor for pancreatic cancer, nearly doubling median overall survival to 13.2...

• Non-relapse mortality after CAR-T reaches 6.8% at median 13.4 months, driven mainly by infections, severe CRS, and ICANS.
• Risk varies by cancer...

The FDA approved zanidatamab (Ziihera) with or without tislelizumab plus chemotherapy for first-line HER2+ advanced gastroesophageal adenocarcinoma,...

The FDA's Rare Pediatric Disease Designation for MZ-1866 highlights the critical unmet need in Pitt Hopkins syndrome and could yield a Priority Review...

Islet cell transplants replace destroyed beta cells with lab-grown or donor cells that produce insulin and regulate blood sugar, though the immune...

Novltex stands out by targeting lipid II, an essential bacterial cell wall component that does not mutate, delivering durable activity against...

Regnase-1 knockout CAR T cells delivered durable tumor control and blocked lung metastasis in relapsed pediatric osteosarcoma models by remodeling the...

• First-line approval: Zanidatamab-hrii plus tislelizumab-jsgr with chemo gains FDA nod for HER2-positive unresectable gastric/GEJ/esophageal...

Advances in presymptomatic plasma biomarkers and systemic Aβ transport research are aligning to support earlier detection and broader intervention...

CAR-T is advancing from experimental use toward refined, broader application.

• Manufacturing gains: Automation, closed systems, and digital tools...

New analysis challenges core assumptions about inflammatory bowel disease, emphasizing modifiable environmental drivers instead.

• Not genetically...

CAR T-cell therapy has expanded from its first FDA approval in 2017 to seven approved products, becoming established in cancer care.

• Key...

• Hereditary angioedema: Lonvo-z single infusion cut attacks 87%, left 62% attack-free, with only grade 1-2 events.
• Duchenne muscular dystrophy:...

A novel framework organizes gastric cancer biomarkers by gastric lineage identity, stemness, and epithelial biology, enabling more precise therapeutic targeting in oncology.

A hormone-targeted therapy combo of anastrozole, palbociclib, trastuzumab, and pertuzumab delivered mainly via pills and under-the-skin injections...

Cancer immunotherapy shows rapid evolution through diverse approaches:

• Mesothelioma combo therapy achieved nearly 40% response rates in a phase II...

GENGLYCOS marks the first FDA-approved gene therapy for glycogen storage disease type Ia, shifting treatment from daily cornstarch management to...

New findings show 3D DNA folding reorganizes in Alzheimer’s, causing more chromatin mingling that reduces neuron gene activity while boosting...